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In a randomized, double blind, crossover study, 10 pa-
tients with stable exercise-induced angina pectoris were
studied during acute and sustained therapy with oral
isosorbide dinitrate. Circulatory changes and exercise
performance were evaluated before and 2 and 6 hours
after medication. Sublingual nitroglycerin was admin-
istered 30 minutes after the 2 and 6 hour exercise tests
and the exercisetest was repeated after another 5 minutes.
Systolicblood pressure at rest 2 hours after isosorbide
dinitrate decreased by 25% during the acute phase, but
by only 11% during the sustained phase (probability [p]
< 0.05). Systolic blood pressure was not decreased fur-
ther by nitroglycerin during acute therapy, but was de-
creased during sustained therapy (p < 0.05). Six hours
after isosorbide dinitrate administration, systolic blood
pressure remained significantly below the control value
during sustained therapy. Treadmill walking time to
moderate angina was significantly prolonged 2 hours
Nitroglycerin administered sublingually has long been rec-
ognized as an effective antianginal agent, but controversy
has existed regarding the value of orally administered or-
ganic nitrate preparations, Studies by Needleman et a1. (I)
suggested that the nitrates were ineffective after oral admin-
istration because of extensive first pass metabolic changes,
However, numerous investigations have demonstrated that
orally administered nitrates produce significant hemody-
namic effects and benefit patients with angina pectoris (2-
7) and left ventricular dysfunction (8-10),
Further controversy exists regarding the development of
nitrate tolerance. Animal experiments (11-18) have shown
a rapid attenuation of the hypotensive response during con-
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after isosorbide dinitrate administration during both the
acute and sustained phases. During the sustained phase,
there was no difference from control values after 6 hours.
Nitroglycerin did not increase walking time 2 1/2 hours
after isosorbide dinitrate during either acute (567 ± 122
versus 560± 119seconds) or sustained (582 ± 115versus
567 ± 129 seconds) therapy, but at 6 1/2 hours, nitro-
glycerin increased walking time from 473 ± 125 to 547
± 107 seconds (p < 0.05) during sustained therapy.
This study demonstrates that 1) tolerance to the
hemodynamic and antianginal effects of isosorbide din-
itrate develops rapidly, 2) nitroglycerin does not further
prolong exercise duration 2 1/2 hours after isosorbide
dinitrate administration, 3) nitroglycerin prolongs ex-
ercise duration when isosorbide dinitrate is no longer
exerting a beneficialeffect, and 4) there is possible cross-
tolerance between isosorbide dinitrate and nitroglycerin.
tinuous therapy with nitroglycerin, a phenomenon that is
time- and dose-dependent. Clinical studies, however, have
shown variable results. Some investigators (19,20) reported
that tolerance to the circulatory effects of the nitrates and
cross-tolerance to nitroglycerin is well established within a
few weeks; others (21-23) failed to demonstrate either tol-
erance to isosorbide dinitrate or cross-tolerance between
isosorbide dinitrate and nitroglycerin. Studies from our lab-
oratory (7,24) have demonstrated that partial circulatory
tolerance to isosorbide dinitrate and cross-tolerance to ni-
troglycerin develop rapidly during regular therapy with iso-
sorbide dinitrate and that partial tolerance to the antianginal
effects of isosorbide dinitrate during therapy is maintained
for only 1 week.
In view of the conflicting evidence regarding nitrate tol-
erance and cross-tolerance among the organic nitrates, we
undertook to reassess the development of tolerance to the
circulatory and antianginal effects of isosorbide dinitrate.
We attempted to determine whether therapy with this agent
modifies the hemodynamic and antianginal effects of sub-
lingual nitroglycerin.
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Methods
Study patients. Ten men, aged 51 to 63 years, with
stable angina pectoris were studied. None of the patients
was hypertensive, had clinical evidence of left ventricular
dysfunction or had clinical or electrocardiographic evidence
of previous myocardial infarction. Six patients had under-
gone coronary arteriography and were found to have more
than 75% stenosis of at least one major coronary artery.
Sublingual nitroglycerin was the only medication the pa-
tients were taking and this was not required on the days of
the investigation. All patients had undergone repeated ex-
ercise testing and were familiar with this procedure. During
the preliminary treadmill exercise test, all patients experi-
enced angina and had horizontal or downsloping ST segment
depression of 0.1 mV or more of at least 0.08 second du-
ration. A computer-assisted system (Marquette Computer
Assisted System for Exercise) was employed that displayed
three simultaneous leads (V}, V6 and aVF). The study was
explained to each patient and informed written consent was
obtained.
Design of investigation. The patients exercised on a
treadmill following the Bruce multistage protocol (25). On
all tests they were encouraged to exercise to an end point
of chest pain of moderate severity, similar to that at which
they would normally stop and take nitroglycerin. During
the study, some patients did not develop angina after drug
administration and stopped exercise because of fatigue. In
the absence of angina, this was considered the end point.
Blood pressure, taken by sphygmomanometry, was recorded
in the supine and standing positions before exercise, at 3
minute intervals during exercise and at the end of exercise.
The treadmill walking time was also recorded at the end of
exercise. The rate-pressure product at that time was cal-
culated as the product of systolic blood pressure and heart
rate.
Precautions were taken to control factors that can produce
changes in exercise tolerance. The temperature in the lab-
oratory was maintained between 20 and 22°C and the pa-
tients' apprehension was reduced by familiarization with the
technique and the staff. The definitive studies were per-
formed after an overnight fast and the patients did not smoke
during the time of investigation. A light lunch without tea
or coffee was provided at noon.
Acute phase. This phase of the study was placebo-con-
trolled and double blind. A control exercise test was per-
formed at 8:30 a.m., and at 9:00 a.m. the patient was ran-
domized to receive either 30 mg of isosorbide dinitrate orally
or a matching placebo. At 11:00 a.m., 2 hours after taking
the medication, the exercise test was repeated. After 30
minutes, the patient received either 0.6 mg of sublingual
nitroglycerin or sublingual placebo. Five minutes later, a
third exercise test was performed. The schedule for the next
3 days was similar. On day 2, the patient received the same
oral medication but the other sublingual medication. On
days 3 and 4, the patient received the other oral medication
and the sublingual medication was again randomized during
these 2 days.
Sustained phase. This phase of the study was also pla-
cebo-controlled and double blind in design. The patient was
given either placebo or isosorbide dinitrate. To reduce the
likelihood of untoward side effects from isosorbide dinitrate,
therapy with isosorbide dinitrate or placebo was initiated
with 1/2 tablet (15 mg isosorbide dinitrate) 4 times daily
for 3 days and then increased to 1 tablet (30 mg isosorbide
dinitrate) 4 times daily for 1 week. Two patients continued
to receive only a 15 mg dose of isosorbide dinitrate because
of headaches. After 1 week of the maximal isosorbide di-
nitrate dose, the patient reported to the laboratory in the
fasting state without taking the morning medication. A con-
trol exercise test was performed at 8:30 a.m. At 9:00 a.m.,
the patient was given the regularly scheduled medication.
Two hours later, an exercise test was performed. After 30
minutes, the patient received either 0.6 mg of sublingual
nitroglycerin or placebo, and 5 minutes later, a third exercise
test was performed. At 3:00 p.m., 6 hours after oral med-
ication, a fourth exercise test was performed. After 30 min-
utes, the patient received the same sublingual medication
given earlier and after another 5 minutes, a final exercise
test was performed. The patient then continued with the
regularly scheduled oral medication and returned the next
day before the morning dose. The schedule for that day was
similar with the patient receiving the same oral medication
but the opposite sublingual medication. The patient was then
given the other oral medication, but following the same
titration schedule and maintained on the maximal dose for
1 week. The patient subsequently returned for 2 days of
testing with the schedule outlined previously.
Statistical analysis. Conventional statistical methods were
used throughout the study. The significance of changes was
studied by Student's t test for paired and unpaired data and
by two-way analysis of variance. Probability (p) values less
than 0.05 were considered significant. All data are expressed
as mean ± standard deviation of the mean.
Results
All 10 patients completed the acute and sustained phases
of the study without complication. None of the patients
experienced angina at rest during the days of exercise test-
ing. Nitroglycerin was not administered except as required
by the protocol.
Acute Phase
Exercise tolerance (Table 1). The control walking time
was not significantly different during the 4 study days. A
significant increase in walking time was observed 2 hours
after oral isosorbide dinitrate but not after placebo. Sublin-
JACC Vol. 2. No 1
July 1983:115-20
Table 1. Walking Time (seconds) to Angina During the Acute Phase of the Study
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Treadmill
Oral Placebo Penod Oral ISDN Period
Exercise Test Day I Day 2 Day 3 Day 4
Control 443 ± 137 423 ± 149 432 ± 112} 464 ± 124
2 hours 446 ± 159 447 ± 15O} 544 ± 143 567 ± 122
2.5 hours
SL placebo 499 ± 158 544 ± 150
SL NTG 533 ± 139 566 ± 119
*p < 0.05
ISDN = tsosorbide dmitrate; NTG = nitroglycenn; SL = sublingual Data represent mean ± standard deviation. The times represent the hours
after morning medication.
gual nitroglycerin did not increase walking time in patients
who had received oral isosorbide dinitrate, but did produce
a significant increase in those who had received oral placebo.
The walking time after nitroglycerin was similar to that
recorded 2 hours after isosorbide dinitrate. Sublingual pla-
cebo produced no change in exercise tolerance.
Blood pressure response (Table 2). The standing sys-
tolic blood pressure was not significantly different before
the control exercise test on the 4 study days. A significant
decrease in systolic pressure was noted 2 hours after oral
isosorbide dinitrate. After sublingual nitroglycerin, systolic
pressure was significantly decreased in patients who had
received oral placebo, but not in those given isosorbide
dinitrate.
Rate-pressure product (Table 2). The exercise rate-
pressure product at the point of moderate angina was not
significantly different on the 4 study days during the control
exercise test. Neither oral isosorbide dinitrate nor placebo
altered the exercise rate-pressure product significantly.
However, there was a significant increase after nitroglycerin
in patients who had received oral placebo, but not in those
given isosorbide dinitrate.
Sustained Phase
Exercise tolerance (Table 3). Walking time during the
control exercise test was not significantly different on the
4 study days; however, a significant increase in walking
time was present 2 hours, but not 6 112 hours, after iso-
sorbide dinitrate administration. Walking time increased by
21% 2 hours after isosorbide dinitrate during this sustained
phase, compared with 26% during the acute phase.
Sublingual nitroglycerin produced a significant increase
in walking time in patients who had received placebo 2 1/2
hours earlier, but not in those given isosorbide dinitrate.
When nitroglycerin was administered 6 1/2 hours after oral
medication, there was a significant increase in walking time
after both placebo and isosorbide dinitrate. The improve-
Table 2. Systolic Blood Pressure at Rest and Rate-Pressure Product at Angina During the Acute Phase of the Study
Oral Placebo Period Oral ISDN Period
Treadmill Exercise
Day I Day 2 Day 3
Test SBP RPP SBP RPP SBP RPP
Control 124 ± 20 210 ± 39 128 ± 14 219 ± 36 123 ± 14} 215 ± 32
2 hours 127 ± 17 227 ± 47 129 ± 14 202< 5} 97 ± 14 207 ± 422.5 hours 128 ± 17 102 ± 16
Pre SL placebo
Post SL placebo 123 ± 14 226 ± 49 96 ± 17 205 ± 39
Pre SL NTG 130 ± 17]*
Post SL NTG 99 ± II 230 ± 51
Day 4
SBP
128 ± 18]*
95 ± 16
94 ± 16
87 ± 13
RPP
216 ± 38
198 ± 43
198 ± 39
*p < 0.05
RPP = rate-pressure product (mm Hg/rmn x 10- 2) ; SBP = standing systolic blood pressure (mm Hg); other abbreviations as in Table l. Systolic
blood pressure was measured just before the control and 2 hour exercise tests and Just before and 5 minutes after sublingual medication. Rate-pressure
product was measured at the time of angina.
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Table 3. Walking Time (seconds) to Angina During the Sustained Phase of the Study
567 ± 129
498 ± 112 473 ± 125}505 ± 137
547 ± 107
Treadmill
Exercise Test
Control
2 hours
2.5 hours
SL placebo
SL NTG
6 hours
6.5 hours
SL placebo
SL NTG
*p < 0.05
Abbreviations as in Table I.
Day I
545 ± 150
584 ± 136
568 ± 123
508 ± 43
514 ± 152
Oral Placebo Period
Day 2
514 ± 145
517 ± 122}
595 ± 128
476 ± 128
587 ± 130J
Oral ISDN Period
Day 3
468 ± 140]*
523 ± 104
547 ± 124
Day 4
482 ± 143]*
582 ± 115
ment in walking time after nitroglycerin was 26% in the
group receiving placebo and 18% in those receiving sus-
tained isosorbide dinitrate; these differences were not sig-
nificant. The exercise end point after nitroglycerin was sim-
ilar whether the patients were receiving isosorbide dinitrate
or placebo or whether the tests were carried out 2 1/2 or 6
112 hours after the oral medication.
Blood pressure response (Table 4). The systolic blood
pressure before exercise testing was similar to that during
the control exercise test on the 4 study days; but it was
significantly lower at both 2 and 6 hours after isosorbide
dinitrate. The systolic blood pressure decreased by 11%
from the control values 2 hours after isosorbide dinitrate
during this phase of the study, which was significantly less
than the 25% decrease noted during the acute phase (p <
0.05). Sublingual nitroglycerin induced a significant de-
crease in systolic blood pressure at 2 112 and 6 112 hours
after both oral isosorbide dinitrate and placebo. At 6 1/2
hours, the decrease in systolic blood pressure after nitro-
glycerin was 19% in the patients receiving placebo, and
14% in those receiving sustained isosorbide dinitrate. Nei-
ther these changes nor the absolute values of blood pressure
after nitroglycerin administration were significantly different.
Rate-pressure product (Table 4). The exercise rate-
pressure product at moderate angina was not significantly
different on the 4 study days during the control period.
Administration of isosorbide dinitrate did not affect the ex-
ercise rate-pressure product at this end point, but after ni-
troglycerin, the rate-pressure product increased significantly
at 6 1/2 hours but not at 2 112 hours after oral placebo.
Sublingual nitroglycerin did not affect the rate-pressureproduct
at either time after oral isosorbide dinitrate.
Table 4. Systolic Blood Pressure at Rest and Rate-Pressure Product at Angina During the Sustained Phase of the Study
Oral Placebo Period Oral ISDN Period
SBP RPP
Day 4
Treadmill Exercise
Test
Control
2 hours
2.5 hours
Pre SL placebo
Post SL placebo
Pre SL NTG
Post SL NTG
6 hours
6.5 hours
Pre SL placebo
Post SL placebo
Pre SL NTG
Post SL NTG
Day I Day 2
SBP RPP SBP
127 ±
13]
220 ± 34 124 ± 10
121 ± 12 223 ± 33
132 ± "}
116 ± 17 *
112 ± 13 225 ± 38
123 ± 18J
98 ± 12 *
124 ± 9 229 ± 41 123 ± 12
124 ± 16J
118 ± 16 * 234 ± 32
119 ± 12}
95 ± 10
Day 3
RPP SBP RPP
221 ± 40 129 ± 13J' 211 ± 42
213 ± 37 114 ± 16 * 213 ± 35
114 ± 20
109 ± II 220 ± 44
225 ± 41
zrs ± 3] 114 ± II 217 ± 34
116 ± JO
112 ± 12 217 ± 37
242 ± 31
132 ± 13J
117 ± II *
115 ± 15J*
98 ± 8
124 ± 9
119 ± 8J*
103 ± 9
*
212 ± 31
228 ± 28
220 ± 36
227 ± 33
228 ± 37
*p < 0.05
Abbreviations as in Table 2
JACC Vol 2, No.1
July 1983:115-20
DALAL ET AL.
NITRATE TOLERANCE
119
Discussion
Circulatory tolerance to nitrates. The present study
evaluates the development of tolerance to isosorbide dini-
trate and the interactions between isosorbide dinitrate and
nitroglycerin on the hemodynamic changes and exercise
duration in patients with angina pectoris secondary to coro-
nary artery disease. The phenomenon of circulatory toler-
ance to nitrates has been well studied in animals. A 10- to
15-fold shift in the blood pressure dose-response curve to
nitroglycerin has been produced in dogs (13,17), rabbits
(11,14) and rats (16,17) after repeated intravenous or sub-
cutaneous administration. In human beings, tolerance to
nitrate headaches in industrial workers has been well doc-
umented (26-28) and recent studies have shown attenuation
of the hemodynamic (7,24) and antianginal (7) effects of
isosorbide dinitrate.
We have previously shown (24) that after the same dose
of isosorbide dinitrate, plasma concentrations are signifi-
cantly higher during sustained than during acute therapy.
In the present study, hemodynamic responses were dimin-
ished and there was less improvement in exercise time dur-
ing the sustained phase of therapy. These attenuated re-
sponses, despite presumably higher plasma isosorbide dinitrate
levels, indicate tolerance.
The improvement in exercise duration at 2 hours but not
at 6 hours after isosorbide dinitrate during the sustained
phase of the study was similar to that of our previous report
(7), but different from that reported by Danahy and Aronow
(22), who noted prolonged exercise duration at 5 hours.
They also observed that the hemodynamic effects of iso-
sorbide dinitrate persisted longer than the antianginal effect.
Our findings support this observation.
In animal experiments, Needleman and Johnson (18) found
that all organic nitrates induced tolerance to the circulatory
effects of nitroglycerin, with isosorbide dinitrate resulting
in the least tolerance. In human beings, the results have
been conflicting. In volunteers given sublingual nitrogly-
cerin, Schelling and Lasagna (20) found that the circulatory
effects were markedly but not completely reduced after ther-
apy with pentaerythrityl tetranitrate. Previous studies from
our laboratory (24) showed that the reduction in blood pres-
sure induced by nitroglycerin was markedly attenuated dur-
ing sustained therapy with isosorbide dinitrate. In contrast,
Aronow and Chesluk (21) were unable to show the devel-
opment of circulatory tolerance to nitroglycerin during sus-
tained therapy with sublingual isosorbide dinitrate. How-
ever, the dose of isosorbide dinitrate (5 mg, 4 times daily)
may have been inadequate to induce significant tolerance.
Danahy and Aronow (22) also failed to show cross-tolerance
to the circulatory and antianginal effects of nitroglycerin
during oral isosorbide dinitrate therapy. However, they stud-
ied the effects of nitroglycerin 14 hours after the last dose
of isosorbide dinitrate.
Mechanism of different effects of nitroglycerin 2 1/2
and 6 1/2 hours after isosorbide dinitrate. In the present
study, the decrease in blood pressure and improvement in
exercise tolerance after nitroglycerin at 6 1/2, but not at 2
1/2 hours after isosorbide dinitrate remains to be understood.
The absence of such changes at 2 1/2 hours has two possible
explanations. First, it could indicate cross-tolerance between
isosorbide dinitrate and nitroglycerin. Second, the hypoten-
sive effect could be limited by homeostatic responses and
the improvement in exercise limited by the ability to improve
the oxygen supply-demand relation. Thus, the failure to alter
these variables at 2 1/2 hours with nitroglycerin could mean
that the maximal nitrate effect had already been achieved
by isosorbide dinitrate. In this situation, it would be im-
possible to demonstrate cross-tolerance.
Six and one-half hours after oral isosorbide dinitrate,
the administration of nitroglycerin led to significant changes
in blood pressure and exercise duration. This could be in-
terpreted as a demonstration of the absence of cross-toler-
ance between these two nitrates. Indeed, such a conclusion
was reached by Lee et al (23), who found improvement in
exercise time after nitroglycerin administration 6 hours after
administering oral isosorbide dinitrate; however, this may
not be a valid explanation for these findings. There is clear
evidence (24) of the development of tolerance during sus-
tained oral isosorbide dinitrate therapy. Despite such tol-
erance, 2 hours after subsequent oral isosorbide dinitrate
administration, there was a decrease in blood pressure, al-
though less marked than during acute therapy, and a pro-
longation of walking time. These findings indicate that ni-
trate tolerance was not complete. It appears that after
subsequent doses, rising plasma isosorbide dinitrate levels
induce further vascular effects that lead to reductions in
blood pressure and improvement in exercise duration. The
nitroglycerin response seen 6 1/2 hours after isosorbide din-
itrate could indicate a similar phenomenon. Such a response
does not confirm or disprove cross-tolerance between these
two organic nitrates. An assessment of the hemodynamic
and antianginal effects of sublingual isosorbide dinitrate
during sustained oral isosorbide dinitrate therapy may clarify
this issue.
There is some hemodynamic evidence in our study to
suggest the development of cross-tolerance in that the de-
crease in systolic blood pressure and the increase in treadmill
walking time after nitroglycerin were less when the patients
were receiving oral isosorbide dinitrate than when receiving
oral placebo. Though not statistically significant, this trend
would suggest the development of cross-tolerance between
the two drugs.
Does nitrate cross-tolerance exist? It is difficult to de-
termine whether cross-tolerance exists, but our observations
are compatible with such a phenomenon. Because it is as-
sumed that organic nitrates have similar mechanisms of
action, and animal studies (18) have demonstrated that cross-
120 DALAL ET AL.
NITRATETOLERANCE
JACCVol 2. No. I
July 1983.11 5-20
tolerance does occur, one would expect this to develop in
human beings as well . The current investigation demon-
strates the development of tolerance to isosorbide dinitrate
and is in accordance with the presence of cross-tolerance
between isosorbide dinitrate and nitroglycerin .
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